PAR

Par Drugs & Chemicals Share Price

 

 

Start SIP in PAR

Start SIP

Performance

  • Low
  • ₹99
  • High
  • ₹102
  • 52 Week Low
  • ₹81
  • 52 Week High
  • ₹135
  • Open Price₹101
  • Previous Close₹102
  • Volume4,492
  • 50 DMA₹95.95
  • 100 DMA₹98.00
  • 200 DMA₹108.99

Investment Returns

  • Over 1 Month + 7.56%
  • Over 3 Month + 5.57%
  • Over 6 Month -1.67%
  • Over 1 Year -30%

Smart Investing Starts Here Start SIP with Par Drugs & Chemicals for Steady Growth!

Invest Now

Par Drugs & Chemicals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 8.8
  • PEG Ratio
  • -0.9
  • Market Cap Cr
  • 122
  • P/B Ratio
  • 1.1
  • Average True Range
  • 4.84
  • EPS
  • 11.3
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.5
  • RSI
  • 56.33
  • MFI
  • 68.91

Par Drugs & Chemicals Financials

Par Drugs & Chemicals Technicals

EMA & SMA

Current Price
₹99.31
-2.79 (-2.73%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹96.13
  • 50 Day
  • ₹95.95
  • 100 Day
  • ₹98.00
  • 200 Day
  • ₹108.99

Resistance and Support

99.83 Pivot Speed
  • R3 103.95
  • R2 102.75
  • R1 101.03
  • S1 98.11
  • S2 96.91
  • S3 95.19

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Par Drugs and Chemicals has an operating revenue of Rs. 106.37 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 18% is great, ROE of 13% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 5% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Par Drugs & Chemicals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-10 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-11-13 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-29 Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-08-07 Quarterly Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
2025-05-08 Audited Results & Others To consider other business matters issue in the ratio of 1:1 of Rs. 10/-.
Date Purpose Remarks
2021-04-28 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Par Drugs & Chemicals F&O

Par Drugs & Chemicals Shareholding Pattern

73.41%
0%
20.03%
6.56%

About Par Drugs & Chemicals

  • NSE Symbol
  • PAR
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Falgun Vallabhbhai Savani
  • ISIN
  • INE04LG01015

Similar Stocks to Par Drugs & Chemicals

Par Drugs & Chemicals FAQs

Par Drugs & Chemicals share price is ₹99 As on 20 February, 2026 | 02:45

The Market Cap of Par Drugs & Chemicals is ₹122.2 Cr As on 20 February, 2026 | 02:45

The P/E ratio of Par Drugs & Chemicals is 8.8 As on 20 February, 2026 | 02:45

The PB ratio of Par Drugs & Chemicals is 1.1 As on 20 February, 2026 | 02:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23